Sessions

• • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational

    • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Spatial Dissection and Multiomics Analysis of the Multiple Myeloma Tumor and Immune Microenvironment

    • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Characterization of the MM and the Tumor Microenvironment

    • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Characterizing Response and Resistance to CAR-T and TCEs

    • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Molecular Characterization of MM and Precursor Disease States

    • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Advancing Therapies in Multiple Myeloma and Waldenström's Macroglobulinemia

    • Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Multiple Myleoma Circulating Tumor Cells, Novel Mechanisms, and Immune Interactions

  • Multiple Myeloma: Clinical and Epidemiological

    • Multiple Myeloma: Clinical and Epidemiological: T Cell Redirecting Therapy Outcomes and Associated Complications

    • Multiple Myeloma: Clinical and Epidemiological: Minimal Residual Disease and Alternative Non-Invasive Bio Marker Evaluations in Myeloma Therapeutics

    • Multiple Myeloma: Clinical and Epidemiological: Monoclonal Gammopathies of Determined Significance - Novel Insights on the Relevance of Gammopathies and Misc

    • Multiple Myeloma: Clinical and Epidemiological: Novel Biomarkers for Treatment Guidance in Multiple Myeloma

    • Multiple Myeloma: Clinical and Epidemiological: Immunological Effects of Sustained Responses in Multiple Myeloma

    • Multiple Myeloma: Clinical and Epidemiological: Molecular and Biological Signatures and Predictors of Outcomes

    • Multiple Myeloma: Clinical and Epidemiological: Predicting Outcome and Side Effects of Novel Immunotherapies in Multiple Myeloma

  • Multiple Myeloma: Prospective Therapeutic Trials

    • Multiple Myeloma: Prospective Therapeutic Trials: Smoldering and Newly Diagnosed Myeloma

    • Multiple Myeloma: Prospective Therapeutic Trials: Relapsed and Refractory Myeloma

  • MGUS, Amyloidosis and Other Non-Myeloma Plasma Cell Dyscrasias

    • MGUS, Amyloidosis & Other Non-Myeloma Plasma Cell Dyscrasias: Clinical & Epidemiological: Screening to Vaccines Spectrum of Plasma Cell Disorders

    • MGUS, Amyloidosis & Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: From Light Chain to Fibril–Novel Diagnostics to Treatments for Amyloidosis